Efficacy and safety of vernakalant in patients with atrial flutter: a randomized, double-blind, placebo-controlled trial

54 adults with atrial flutter (AFL)

Vernakalant 3.0 mg/kg 10-minute intravenous infusion, followed by a second 10-minute infusion of 2.0 mg/kg if AFL or AF persisted after a 15-minute observation period

Matching placebo infusions

Proportion of patients who had treatment-induced conversion of AFL to sinus rhythm for a minimum duration of 1 min within 90 min after the start of the first infusionsurrogate